UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Domain I of β2GPI is capable of blocking serum IgA antiphospholipid antibodies binding in vitro: an effect enhanced by PEGylation

Albay, A; Artim-Esen, B; Pericleous, C; Wincup, C; Giles, I; Rahman, A; McDonnell, T; (2019) Domain I of β2GPI is capable of blocking serum IgA antiphospholipid antibodies binding in vitro: an effect enhanced by PEGylation. Lupus 10.1177/0961203319851571. (In press). Green open access

[thumbnail of Rahman_Domain I of β2GPI is capable of blocking serum IgA antiphospholipid antibodies binding in vitro. An effect enhanced by PEGylation_AOP.pdf]
Preview
Text
Rahman_Domain I of β2GPI is capable of blocking serum IgA antiphospholipid antibodies binding in vitro. An effect enhanced by PEGylation_AOP.pdf - Published Version

Download (494kB) | Preview

Abstract

OBJECTIVES: This study aims to inhibit antiphospholipid syndrome (APS) serum derived IgA anti-beta-2-glycoprotein I (aβ2GPI) binding using Domain I (DI). METHODS: Serum from 13 APS patients was tested for IgA aβ2GPI and Anti-Domain I. Whole IgA was purified by peptide M affinity chromatography from positive serum samples. Serum was tested for IgA aβ2GPI binding in the presence and absence of either DI or of two biochemically modified variants containing either 20 kDa of poly(ethylene glycol) (PEG) or 40 kDa of PEG. RESULTS: Significant inhibition with DI was possible with average inhibition of 23% ( N = 13). Further inhibitions using 20 kDa PEG-DI and 40 kDa PEG-DI variants showed significant inhibition ( p = 0.0001) with both the 40 kDa PEG-DI and 20 kDa PEG-DI variants showing increased inhibition compared with DI alone ( p = 0.0001 and p = 0.001, n = 10). CONCLUSIONS: Inhibition of IgA aβ2GPI by DI is possible and can be enhanced by biochemical modification in a subset of patients.

Type: Article
Title: Domain I of β2GPI is capable of blocking serum IgA antiphospholipid antibodies binding in vitro: an effect enhanced by PEGylation
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1177/0961203319851571
Publisher version: https://doi.org/10.1177%2F0961203319851571
Language: English
Additional information: © The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 License (http://www.creativecommons.org/licenses/by/4.0/).
Keywords: Antiphospholipid syndrome, Domain I, PEGylation
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation
UCL > Provost and Vice Provost Offices > UCL BEAMS
UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Engineering Science
UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Engineering Science > Dept of Biochemical Engineering
URI: https://discovery.ucl.ac.uk/id/eprint/10075465
Downloads since deposit
31Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item